BOULDER, Colo., Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to develop and commercialize a kit-based version of Foresight's CLARITY™ assay, with the goal of enabling global in vitro diagnostic (IVD) and companion diagnostic (CDx) applications in lymphoma and other hematological malignancies.Th ...

Core Insights - Creative Realities, Inc. reported a first quarter revenue of $9.7 million for fiscal 2025, down from $12.3 million in the same period of fiscal 2024, primarily due to installation timing issues [4][10] - The company announced a significant contract with a well-known restaurant chain to transform hundreds of locations across the U.S., which is expected to drive growth in the second half of 2025 [3][10] - The company ended the first quarter with an annual recurring revenue (ARR) of approximately $17.3 million, an increase from $16.8 million at the end of 2024 [5][10] Financial Performance - Consolidated gross profit for the first quarter was $4.5 million, compared to $5.8 million in the prior-year period, with a gross margin of 45.7% [5][10] - Operating loss for the first quarter was approximately $0.7 million, compared to a loss of $0.1 million in the same period last year [7][10] - The company reported a net income of $3.4 million, or $0.32 per diluted share, in the first quarter of fiscal 2025, compared to a net loss of $0.1 million, or $(0.01) per diluted share, in the prior-year period [7][10] Cost Management - Sales and marketing expenses decreased to $1.2 million from $1.5 million in the prior-year period, while general and administrative expenses fell to $3.9 million from $4.4 million [6][10] - Adjusted EBITDA for the first quarter was $0.5 million, down from $0.8 million in the prior-year period [8][10] Balance Sheet and Debt - As of March 31, 2025, the company had cash on hand of approximately $1.1 million, compared to $1.0 million at the end of 2024 [11][10] - Total debt was approximately $23.2 million, down from $25.8 million at the start of the fiscal year, primarily due to a $5.8 million reduction in contingent liabilities [11][10] - The trailing twelve-month gross and net leverage ratios utilizing Adjusted EBITDA were 4.91x and 4.67x, respectively, compared to 2.59x and 2.39x at the beginning of 2025 [12][10]

SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 & Recent Highlights Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024Ended the quarter with 558 total active accounts Achi ...

LOUISVILLE, Ky., May 05, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. ("Creative Realities," "CRI," or the "Company") (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial results for the three months ended March 31, 2025 before the market open on Wednesday, May 14, 2025. A conference call to review the results is scheduled for Wednesday, May 14, 2025, at 9:00 am Eastern Time, which will include prepared remarks and materials from ...

Core Insights - Ceribell, Inc. has received FDA 510(k) clearance for its Ceribell Clarity™ algorithm, making it the first AI-powered point-of-care EEG system capable of detecting electrographic seizures in patients aged 1 and older [1][2][3] - The Clarity algorithm is designed to provide comprehensive seizure detection across the largest age range ever addressed by such technology, enhancing the capabilities of hospitals, particularly in emergency departments and ICUs [1][3] - The pediatric clearance was supported by EEG data from over 1,700 patients, marking it as the largest validation dataset for FDA clearance of a seizure detection system [1][3] Company Overview - Ceribell is a medical technology company focused on improving the diagnosis and management of serious neurological conditions through its innovative EEG platform [6] - The Ceribell System combines portable hardware with AI-powered algorithms to enable rapid diagnosis and continuous monitoring of neurological conditions, currently utilized in intensive care units and emergency rooms across the U.S. [6] Industry Impact - The FDA clearance is expected to significantly impact the lives of critically ill children, who are at high risk for preventable brain injury due to seizures [3] - Non-convulsive seizures, which can only be detected through EEG, require prompt identification and treatment to prevent brain injury, highlighting the importance of rapid EEG access [3]